Related references
Note: Only part of the references are listed.Relationship between Tumor Enhancement, Edema, IDH1 Mutational Status, MGMT Promoter Methylation, and Survival in Glioblastoma
J. A. Carrillo et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2012)
Quantitative analysis of neovascular permeability in glioma by dynamic contrast-enhanced MR imaging
Zhongzheng Jia et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2012)
MGMT expression and promoter methylation status may depend on the site of surgical sample collection within glioblastoma: a possible pitfall in stratification of patients?
Alessandro Della Puppa et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Continuing the search for MR imaging biomarkers for MGMT promoter methylation status: conventional and perfusion MRI revisited
Ajay Gupta et al.
NEURORADIOLOGY (2012)
Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging
Won-Jin Moon et al.
NEURORADIOLOGY (2012)
Apparent Diffusion Coefficient Histogram Analysis Stratifies Progression-Free Survival in Newly Diagnosed Bevacizumab-Treated Glioblastoma
W. B. Pope et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2011)
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Michael Weller et al.
NATURE REVIEWS NEUROLOGY (2010)
An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging
Sylvia Drabycz et al.
NEUROIMAGE (2010)
MGMT promoter methylation in malignant gliomas
Markus J. Riemenschneider et al.
TARGETED ONCOLOGY (2010)
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
Alba A. Brandes et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition
Qingyu Zhou et al.
CLINICAL CANCER RESEARCH (2007)
Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival
Marica Eoli et al.
CLINICAL CANCER RESEARCH (2007)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide
ME Hegi et al.
CLINICAL CANCER RESEARCH (2004)
Generating mutations but providing chemosensitivity:: the role of O6-methylguanine DNA methyltransferase in human cancer
M Esteller et al.
ONCOGENE (2004)
Share Paper
